Novartis and GSK team in $14.5b IP exchange
Novartis and GSK have agreed to create a consumer healthcare business in a joint venture that involves the exchange of assets worth billions of dollars.
Depomed settles with generics over Gralise dispute
Depomed, a California-based pharmaceutical company, has settled litigation with two of three companies that sought to launch generic versions of its Gralise (gabapentin) product before patents covering it expire.
Aurobindo Pharma sued over Angiomax
US-based The Medicines Co has sued Aurobindo Pharma after claims the Indian pharmaceutical company infringed two patents related to its heart drug Angiomax (bivalirudin).
Generics file Teva response in Copaxone battle
A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).
UK High Court strikes down Herceptin patents
The UK High Court has invalidated two patents covering Roche’s breast cancer drug Herceptin (trastuzumab) after a challenge by generic drug maker Hospira.
Mintz Levin adds three in Boston
Law firm Mintz Levin Cohn Ferris Glovsky and Popeo PC has added three partners to its IP team.
IP group joins O'Melveny’s New York office
US law firm O’Melveny & Myers LLP has hired Lisa Barons Pensabene, Marc Pensabene, and Filko Prugo at its New York office.
Mallinckrodt picks up Acthar in Questcor merger
Dublin-based Mallinckrodt Pharmaceuticals has announced it will buy US biopharmaceutical company Questcor Pharmaceuticals for $5.6 billion.
Purdue sues Teva to block OxyContin challenge
OxyContin (oxycodone hydrochloride) maker Purdue Pharma has filed suit against Teva to stop the generic drug maker trying to litigate claims to a patent for which it had filed a Paragraph III certification.
Teva asks US Supreme Court to stay ruling in Copaxone case
Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.
